Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. APLS
stocks logo

APLS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
201.11M
-5.37%
-0.384
+32.5%
193.29M
+15.88%
-0.475
-35.81%
212.46M
+19.03%
-0.344
+4.24%
Estimates Revision
The market is revising Upward the revenue expectations for Apellis Pharmaceuticals, Inc. (APLS) for FY2025, with the revenue forecasts being adjusted by 5.92% over the past three months. During the same period, the stock price has changed by -21.12%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.92%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-178.08%
In Past 3 Month
Stock Price
Go Down
down Image
-21.12%
In Past 3 Month
Wall Street analysts forecast APLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLS is 33.07 USD with a low forecast of 18.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast APLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLS is 33.07 USD with a low forecast of 18.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
6 Hold
1 Sell
Moderate Buy
Current: 22.190
sliders
Low
18.00
Averages
33.07
High
52.00
Current: 22.190
sliders
Low
18.00
Averages
33.07
High
52.00
JPMorgan
Anupam Rama
Overweight
downgrade
$40 -> $36
2025-11-05
Reason
JPMorgan
Anupam Rama
Price Target
$40 -> $36
2025-11-05
downgrade
Overweight
Reason
JPMorgan analyst Anupam Rama lowered the firm's price target on Apellis to $36 from $40 and keeps an Overweight rating on the shares. The firm updated the company's model.
Wolfe Research
Andy Chen
Peer Perform
initiated
2025-11-05
Reason
Wolfe Research
Andy Chen
Price Target
2025-11-05
initiated
Peer Perform
Reason
Wolfe Research analyst Andy Chen initiated coverage of Apellis with a Peer Perform rating without a price target. The firm says the company's Syfovre revenue has been "flattish," with the launch is heading into a "high-scatter" indication where patient-finding may be a challenge. It sees low revenue growth holding back the shares.
Mizuho
Neutral
downgrade
$24 -> $19
2025-11-03
Reason
Mizuho
Price Target
$24 -> $19
2025-11-03
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Apellis to $19 from $24 and keeps a Neutral rating on the shares following Q3 results. While Empaveli's launch in C3G/IC-MPGN has gotten off to a "promising start," Syfovre's growth remains challenged, which is "more core to our thesis," the analyst tells investors in a post-earnings note.
TD Cowen
Buy
downgrade
$50 -> $45
2025-10-31
Reason
TD Cowen
Price Target
$50 -> $45
2025-10-31
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Apellis to $45 from $50 and keeps a Buy rating on the shares. The firm noted Q3 Syfovre sales of $151MM (0% Q/Q) were modestly below consensus ($156MM) and management guided to steady but measured growth in future quarters.
H.C. Wainwright
Buy
downgrade
$57 -> $45
2025-10-31
Reason
H.C. Wainwright
Price Target
$57 -> $45
2025-10-31
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Apellis to $45 from $57 and keeps a Buy rating on the shares following the Q3 report. The firm says Syfovre's softer Q3 performance "warrants further tracking."
Citi
Buy
to
Buy
downgrade
$52 -> $45
2025-10-31
Reason
Citi
Price Target
$52 -> $45
2025-10-31
downgrade
Buy
to
Buy
Reason
Citi lowered the firm's price target on Apellis to $45 from $52 and keeps a Buy rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Apellis Pharmaceuticals Inc (APLS.O) is -14.92, compared to its 5-year average forward P/E of -26.16. For a more detailed relative valuation and DCF analysis to assess Apellis Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-26.16
Current PE
-14.92
Overvalued PE
7.82
Undervalued PE
-60.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-19.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
110.02
Undervalued EV/EBITDA
-148.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
36.37
Current PS
0.00
Overvalued PS
90.10
Undervalued PS
-17.36
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 132.99% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

APLS News & Events

Events Timeline

(ET)
2025-12-03
17:10:00
Apellis Pharmaceuticals Announces Positive EMPAVELI Study Results
select
2025-11-12 (ET)
2025-11-12
07:22:23
Apellis Reveals 5-Year GALE Data Indicating SYFOVRE Slowed GA Progression
select
2025-10-30 (ET)
2025-10-30
12:00:40
Apellis Experiences a 24.8% Decline
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04Globenewswire
Apellis Receives FDA Approval for EMPAVELI to Treat C3G, Achieving 68% Reduction in Proteinuria
  • Clinical Trial Success: Apellis' EMPAVELI demonstrated a 68% reduction in proteinuria in the VALIANT study, significantly outperforming the placebo group, marking a major breakthrough in the treatment of C3G and IC-MPGN that could transform patient quality of life.
  • Kidney Function Stabilization: Patients treated with EMPAVELI achieved a stabilization in kidney function with a +6.3 mL/min/1.73 m² improvement, showcasing its potential to delay kidney failure progression and addressing urgent treatment needs among patients.
  • C3 Deposit Clearance: A remarkable 71% of EMPAVELI-treated patients achieved complete clearance of C3 deposits, indicating the drug's effectiveness in improving key pathological markers and potentially guiding future treatment strategies.
  • Broad Market Potential: As the first FDA-approved treatment for C3G and IC-MPGN, EMPAVELI is expected to attract a growing number of patients starting treatment, further enhancing Apellis' market share in the rare disease sector.
[object Object]
Preview
9.0
12-04Newsfilter
Apellis Receives FDA Approval for EMPAVELI to Treat C3G with 68% Proteinuria Reduction
  • Clinical Trial Success: The VALIANT study demonstrated that EMPAVELI significantly benefits C3G and IC-MPGN patients, achieving a 68% reduction in proteinuria, marking a major breakthrough that could transform patient quality of life.
  • Kidney Function Stabilization: EMPAVELI stabilized kidney function with a +6.3 mL/min/1.73 m² increase in eGFR, indicating its potential to delay kidney failure and reduce the need for dialysis or transplantation among patients.
  • Good Safety Profile: The VALIANT study confirmed EMPAVELI's safety profile consistent with previous data, with no reported cases of meningococcal infections, enhancing physician confidence in its clinical application.
  • Broad Market Potential: As the first FDA-approved treatment for C3G and IC-MPGN, EMPAVELI is expected to attract a significant patient population, addressing the urgent market demand for new therapies and driving long-term growth for Apellis.
[object Object]
Preview
9.0
11-13Benzinga
This Underrated Biotech May Have Just Demonstrated the Longevity of Its Leading Drug

  • Post Hoc Analysis Results: Apellis Pharmaceuticals announced that a post hoc analysis of the GALE extension study showed Syfovre significantly delayed geographic atrophy lesion growth by approximately 1.5 years compared to projected sham treatments, with monthly and every-other-month dosing resulting in 31% and 27% reductions in lesion growth, respectively.

  • Market Performance and Analyst Insights: Despite a 4% quarter-over-quarter growth in Syfovre demand and a net product revenue of $150.9 million, Apellis' stock has faced challenges due to a lack of copay assistance. Analysts view this as a buying opportunity, highlighting Syfovre's potential for long-term market share growth against competitors.

  • Long-Term Outlook: Analysts believe that Syfovre's superior efficacy over Astellas Pharma's Izervay positions it well for significant market share as physicians prioritize effectiveness over safety, indicating a positive long-term outlook for the drug.

  • Stock Performance: Apellis' stock was trading up by 2.52% to $20.01, reflecting a potential value disconnect as investors focus on short-term competitive pressures rather than the drug's long-term prospects.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Apellis Pharmaceuticals Inc (APLS) stock price today?

The current price of APLS is 22.19 USD — it has increased 4.42 % in the last trading day.

arrow icon

What is Apellis Pharmaceuticals Inc (APLS)'s business?

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

arrow icon

What is the price predicton of APLS Stock?

Wall Street analysts forecast APLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLS is 33.07 USD with a low forecast of 18.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Apellis Pharmaceuticals Inc (APLS)'s revenue for the last quarter?

Apellis Pharmaceuticals Inc revenue for the last quarter amounts to 458.58M USD, increased 132.98 % YoY.

arrow icon

What is Apellis Pharmaceuticals Inc (APLS)'s earnings per share (EPS) for the last quarter?

Apellis Pharmaceuticals Inc. EPS for the last quarter amounts to 1.66 USD, decreased -460.87 % YoY.

arrow icon

What changes have occurred in the market's expectations for Apellis Pharmaceuticals Inc (APLS)'s fundamentals?

The market is revising Upward the revenue expectations for Apellis Pharmaceuticals, Inc. (APLS) for FY2025, with the revenue forecasts being adjusted by 5.92% over the past three months. During the same period, the stock price has changed by -21.12%.
arrow icon

How many employees does Apellis Pharmaceuticals Inc (APLS). have?

Apellis Pharmaceuticals Inc (APLS) has 705 emplpoyees as of December 05 2025.

arrow icon

What is Apellis Pharmaceuticals Inc (APLS) market cap?

Today APLS has the market capitalization of 2.81B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free